Life Stem Genetics, Inc. (OTCBB:LIFS) announced today a strategic
collaborative agreement with American CryoStem Corporation,
(OTCBB:CRYO). CRYO is a leading developer, marketer and global licensor
of patented adipose tissue-based cellular technologies for the
Regenerative and Personalized Medicine industries.
Adipose tissue is an anatomical term for loose connective tissue (fat)
composed of adipocytes (cells). It is used in LIFS stem cell procedures
and currently is extracted via liposuction each time a patient has a
treatment. This collaboration will give our physician’s network the
ability to store a patient’s adipose tissue for future regenerative
medicine applications after only one extraction process. In the absence
of future liposuction procedures, the patient’s recovery time is
lessened and additional procedure costs are reduced.
This collaboration will provide the Company’s physicians and medical
clinics access to a FDA registered laboratory and the science of tissue
collection, processing and long term storage of their patient’s adipose
tissue sample collected at the point of care.
American CryoStem’s ATGRAFT™ tissue samples are processed and prepared
upon arrival at their FDA registered laboratory based in Mt. Laurel,
N.J., tested for adipocyte and cellular viability, and stored free of
charge for six months. Long term storage fees will be billed directly to
the patient by American CryoStem with revenue shared with LIFS. Stored
patient samples retrieved by LIFS physicians will be shipped, ready for
use without any additional processing.
Life Stem Genetics Chief Medical Stem Cell Specialist, James Vanden
Bosch, BHA, commented, “This relationship secured with American CryoStem
by Life Stem Genetics advances our physician’s treatment protocols from
traditionally collecting and processing patients adipose tissue in the
same day to establishing a treatment program not dictated by a single
liposuction procedure.” Mr. Vanden Bosch further commented, “Patients
can now visit a clinic and have future treatments with the same high
quality adipose tissue.” he adds.
The Company expects to begin internal validation of the ATGRAFT™ service
in the coming weeks prior to a full roll-out of this new offering.
Additional updates about Life Stem Genetics and American CryoStem will
be announced as this synergistic relationship continues to develop.
About Life Stem Genetics
Life Stem Genetics ("LSG") is a progressive healthcare company focused
on Adult Stem Cell (ASC) healing therapies. For decades, stem cells have
been utilized in the successful treatment of a variety of ailments.
Today, advanced ASC therapies are being offered to patients as an
efficient and painless alternative treatment for a wide range of
ailments including, but not limited to, orthopedic injuries,
neurological disorders such as Parkinson's and Alzheimer's, cancer,
arthritis, diabetes, multiple sclerosis, as well as age management.
Adult Stem Cell therapies and LSG's proprietary techniques are
experiencing some of the best results in the industry in helping to
repair or reprogram damaged or diseased tissues and organs. Life Stem's
ASC specialist has performed thousands of stem cell treatments including
some of the top names in PGA golf, NFL football, NBA basketball, and
Major League Baseball. LSG will offer its proprietary treatments through
a series of affiliate doctors and medical clinics with 60 affiliated
clinics thus far. LSG's mission is to develop a comprehensive approach
to the treatment and maintenance of diseases while breaking free from
the medical insurance maze by tapping into an affordable private-pay
sector.
Contrarian Press, an established publisher, has been engaged by Life
Stem Genetics to assist with identification of potential market
participants who may be interested in learning more about the company
and its securities. Updated disclaimer and disclosure information is
available at the publisher's website and at the following link: http://www.contrarianwealthcoalition.com/guide/LIFS.pdf
For a copy of LIFS logo is available at: http://www.lifestemgenetics.com/wp-content/themes/LifeStemGenetics/images/life-stem-genetics-logo.png
About American CryoStem Corporation
A pioneer in the fields
of Regenerative and Personalized Medicine, American
CryoStem Corporation is engaged in building a worldwide network
of state-of-the-art clinical laboratories dedicated to processing,
commercial bio-banking and manufacturing cellular applications using
autologous adipose (fat) tissue and Adipose-Derived Regenerative Cells
(ADRCs). The Company maintains a strong, strategic portfolio of
intellectual property, patent applications and proprietary operating
procedural processes that form its Adipose Tissue Processing Platform,
which in turn, supports the growing pipeline of biologic products and
processes, clinical services and international licensing opportunities.
More specifically, this platform enables the cryopreservation of an
individual's adipose tissue which when needed can be further clinically
processed into Stromal Vascular Fraction (SVF), which contains ADRCs,
other regenerative cells, including white blood cells, endothelial
cells, smooth muscle cells, pericytes, fibroblasts and pre-adipocytes,
among others. Through its ACS Laboratories division, the Company
operates its flagship FDA registered, cGMP compliant human tissue
processing, cryo-storage and cell culture and differentiation media
development facility in Mount Laurel, New Jersey.
For more information, please visit www.americancryostem.com
and www.acslaboratories.com.
Forward Looking Statements
This press release may contain
forward-looking statements, including information about management's
view of American CryoStem Corporation’s (“the Company”) future
expectations, plans and prospects. In particular, when used in the
preceding discussion, the words "believes," "expects," "intends,"
"plans," "anticipates," or "may," and similar conditional expressions
are intended to identify forward-looking statements. Any statements made
in this press release other than those of historical fact, about an
action, event or development, are forward-looking statements. These
statements involve known and unknown risks, uncertainties and other
factors, which may cause the results of the Company, its subsidiaries
and concepts to be materially different than those expressed or implied
in such statements. Unknown or unpredictable factors also could have
material adverse effects on the Company’s future results. The
forward-looking statements included in this press release are made only
as of the date hereof. The Company cannot guarantee future results,
levels of activity, performance or achievements. Accordingly, you should
not place undue reliance on these forward-looking statements. Finally,
the Company undertakes no obligation to update these statements after
the date of this release, except as required by law, and also takes no
obligation to update or correct information prepared by third parties
that are not paid for by American CryoStem Corporation.
This press release contains "forward-looking statements" within the
meaning of the "safe-harbor" provisions of the Private Securities
Litigation Reform Act of 1995 that are not historical facts. These
statements can be identified by the use of forward-looking terminology
such as "believe," "expect," "may", "could", "estimates", "will,"
"should," "project," "plan," "seek," "intend," or "anticipate" or the
negative thereof or comparable terminology, and include discussions of
strategy, and statements about industry trends and the Company's future
performance, operations, and products. Such statements involve known and
unknown risks, uncertainties and other factors that could cause the
Company's actual results to differ materially from the results expressed
or implied by such statements. Such risks and uncertainties include,
without limitation, market acceptance of the Company's stem cell therapy
treatment program; the Company's compliance with applicable statutes and
regulations: the Company's reliance on third-party contractors to
provide suitable treatment facilities; the Company's ability to expand
its network of participating clinics and doctors; the Company's ability
to develop an effective marketing strategy; the Company's ability to
control and reduce advertising and marketing costs; the Company's
ability to develop and increase awareness of its brand; the Company's
ability to protect its trademarks; and the success of the Company's
marketing focus to patients, doctors and clinics. For a discussion of
these and other risks and uncertainties see "Risk Factors" and
"Description of Business" in the Company's public filings with the SEC.
Although the Company believes that the expectations reflected in such
forward-looking statements are reasonable, there can be no assurance
that such expectations will prove to be correct. The Company has no
obligation to update the forward-looking information contained in this
press release.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20131122005162r1&sid=ntxv4&distro=nx)
Copyright Business Wire 2013